Akihiro Ginnaga

Title: Akihiro Ginnaga: Innovator in Pertussis Vaccine Development

Introduction

Akihiro Ginnaga is a notable inventor based in Kumamoto, Japan. He has made significant contributions to the field of vaccine development, particularly in the area of pertussis vaccines. With a total of 4 patents to his name, Ginnaga's work has had a substantial impact on public health.

Latest Patents

Ginnaga's latest patents include a method for preparing pertussis toxin toxoid using HcHo and amino acids. This innovative method involves treating pertussis toxin with formaldehyde in the presence of lysine or glycine combined with N-acetyltriptophan. The resulting toxoid does not exhibit toxicity reversion, making it highly suitable for use in pertussis vaccines. Another significant patent is for the purification of LPF-HA (Leucocytosis promoting far hemagglutinin). This improved method allows for the purification of LPF-HA on an industrial scale by contacting a LPF-HA-containing solution from Bordetella pertussis culture media with specific gels. The method ensures a highly purified LPF-HA free from other proteins, lipids, saccharides, and undesirable endotoxins, making it ideal for producing various reagents, medicines, and pertussis vaccines.

Career Highlights

Throughout his career, Ginnaga has worked with esteemed organizations such as the Juridical Foundation the Chemo-sero-therapeutic Research Institute and the Chemo-sero-therapeutic Research Institute. His work in these institutions has been pivotal in advancing research and development in vaccine technology.

Collaborations

Ginnaga has collaborated with notable colleagues, including Shin Sakuma and Tsukasa Nishihara. These partnerships have contributed to the success of his research and innovations.

Conclusion

Akihiro Ginnaga's contributions to vaccine development, particularly in pertussis, highlight his role as a significant inventor in the field. His innovative methods and collaborations continue to influence public health positively.